CFDE Data Portal | Search ARB2A-DT

	Label	Description
	ARB2A-DT Gene (Entity type)	ENSG00000286577 - ARB2A divergent transcript
	GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 6 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE143782 calcitriol 7 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196343 metformin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 8 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE199862 Chk1 inhibition 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE183535 MYC inhibition HeLa 0 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS

ARB2A-DT

ENSG00000286577 - ARB2A divergent transcript

GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn

A Gene Set from LINCS

GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 6 v 7 human dn

A Gene Set from LINCS

GSE143782 calcitriol 7 v 11 human dn

A Gene Set from LINCS

GSE196343 metformin 1 v 0 human dn

A Gene Set from LINCS

GSE48812 sulforaphane 2 v 5 human up

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 8 v 5 human dn

A Gene Set from LINCS

GSE199862 Chk1 inhibition 3 v 1 human dn

A Gene Set from LINCS

GSE183535 MYC inhibition HeLa 0 v 6 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.